26. August 2021 Meghan Sapp

TriAltus Bioscience secures US patent for protein delivery system

In Alabama, TriAltus Bioscience announced that the U.S Patent and Trademark Office has issued U.S. Patent No 10,759,830 for its CLīM affinity tag system, which delivers proteins with ultra-high purity and yield in a single step. 

The patent, entitled “Bacterial colicin-immunity protein purification system,” covers mutations made to colicin E7, a naturally occurring e.coli protein, making it suitable for use as a novel tag. This novel methodology overcomes many shortcomings of other tag-based purification systems. CLīM technology is based on the ultra-high binding affinity between the engineered colicin E7 (CL7) and its immunity protein Im7. This Cl7-Im7 complex is the platform for many current and potential products and applications including plasmids, affinity purification resin, recombinant proteins, assays, and genomics. Current users include academic scientists, hospital systems, and biopharmaceutical and agricultural biotech companies.

This patent will help TriAltus to develop its CLīM system, and explore new applications including membrane purification, vaccine delivery, and biofuel production.

The technology is licensed from the University of Alabama at Birmingham.